The validation of [11C]PXT012253 as a PET radioligands for the mGlu4 will enable to study mGlu4 binding in vivo in patients, e.g. levodopa-induced dyskinesia in Parkinson’s disease and as a target for novel drugs in Schizophrenia and depression. Here, GRM4 is linked to major depressive disorder.